Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have been given a consensus recommendation of “Buy” by the six analysts that are covering the company, MarketBeat reports.

Scientists are now looking to bacteriophage — viruses that infect bacteria — and their potential to treat drug-resistant ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Rani Therapeutics Holdings (RANI – Research Report), ...

Despite a significant decrease in cash reserves, Rani Therapeutics Holdings Inc (RANI) focuses on advancing its promising RaniPill technology and strategic programs.

Cash, cash equivalents and marketable securities as of December 31, 2024 totaled $27.6M, compared to $48.5M for the year ended December 31, ...

("Rani Therapeutics” or "Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

Rani Therapeutics Hldgs RANI will release its quarterly earnings report on Monday, 2025-03-31. Here's a brief overview for ...

1 Day RANI -0.69% DJIA -0.31% Russell 2K -1.03% Health Care/Life Sciences 0.63% ...

SAN JOSE, Calif. - Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $81 million, has announced promising preclinical study ...